Trials / Completed
CompletedNCT05749380
Pharmacokinetics and Safety of AmBisome and DKF-5122
Bioequivalence Study to Evaluate Pharmacokinetics and Safety of AmBisome and DKF-5122 in Indicated Patients and Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Dongkook Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the Safety and Pharmacokinetic Characteristics of AmBisome and DKF-5122
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AmBisome | Reference, dose of 3 mg/kg. |
| DRUG | DKF-5122 | Test, dose of 3 mg/kg |
Timeline
- Start date
- 2020-09-07
- Primary completion
- 2022-01-28
- Completion
- 2022-01-28
- First posted
- 2023-03-01
- Last updated
- 2023-03-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05749380. Inclusion in this directory is not an endorsement.